US2006110324A1PendingUtilityA1

Human anti-epidermal growth factor receptor single-chain antibodies

53
Assignee: UAB RESEARCH FOUNDATIONPriority: Oct 13, 2000Filed: Dec 23, 2005Published: May 25, 2006
Est. expiryOct 13, 2020(expired)· nominal 20-yr term from priority
Inventors:Kevin RaischDavid T. CurielJames Bonner
C07K 2317/622C07K 2317/21A61K 51/103A61K 2039/505C07K 16/2863
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by ELISA as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal growth factor receptor and the truncated and/or mutated epidermal growth factor receptor on human cells. These anti-EGFR-scFvs are useful as therapeutic and/or diagnostic agents.

Claims

exact text as granted — not AI-modified
1 . An isolated human anti-epidermal growth factor receptor single-chain antibody having the sequence of SEQ ID No. 1 or biologically functional fragment thereof, wherein said antibody binds to the extracellular domain of epidermal growth factor receptor.  
     
     
         2 . A pharmaceutical composition comprising the anti-epidermal growth factor receptor single-chain antibody of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         3 . The pharmaceutical composition of  claim 2 , further comprising a therapeutic agent.  
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein said therapeutic agent is a toxin, a chemotherapeutic agent, a radioisotope, or a gene therapy vector.  
     
     
         5 . The pharmaceutical composition of  claim 2 , further comprising a diagnostic agent.  
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein said diagnostic agent is a radioisotope or a transition metal.  
     
     
         7 . A method of treating a tumor, comprising: 
 administering to a patient in need of such treatment an effective amount of an anti-epidermal growth factor receptor single-chain antibody of  claim 1 .    
     
     
         8 . The anti-epidermal growth factor receptor single-chain antibody of  claim 1 , further comprising a radiolabel.  
     
     
         9 . A method for the diagnostic location and assessment of tumor growth, comprising: 
 administering to a patient in need of such diagnostic treatment an effective amount of an anti-epidermal growth factor receptor single-chain antibody of  claim 8 .    
     
     
         10 . An isolated DNA encoding the anti-epidermal growth factor receptor single-chain antibody of  claim 1 .  
     
     
         11 . An expression vector comprising the isolated DNA of  claim 10 .  
     
     
         12 . A human anti-epidermal growth factor receptor single-chain antibody having the sequence of SEQ ID No. 2 or biologically functional fragment thereof, wherein said antibody binds to the extracellular domain of epidermal growth factor receptor.  
     
     
         13 . A pharmaceutical composition comprising the anti-epidermal growth factor receptor single-chain antibody of  claim 12  and a pharmaceutically acceptable carrier.  
     
     
         14 . The pharmaceutical composition of  claim 13 , further comprising a therapeutic agent.  
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein said therapeutic agent is a toxin, a chemotherapeutic agent, a radioisotope, or a gene therapy vector.  
     
     
         16 . The pharmaceutical composition of  claim 13 , further comprising a diagnostic agent.  
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein said diagnostic agent is a radioisotope or a transition metal.  
     
     
         18 . A method of treating a tumor, comprising: 
 administering to a patient in need of such treatment an effective amount of an anti-epidermal growth factor receptor single-chain antibody of  claim 12 .    
     
     
         19 . The anti-epidermal growth factor receptor single-chain antibody of  claim 12 , further comprising a radiolabel.  
     
     
         20 . A method for the diagnostic location and assessment of tumor growth, comprising: 
 administering to a patient in need of such diagnostic treatment an effective amount of an anti-epidermal growth factor receptor single-chain antibody of  claim 19 .    
     
     
         21 . An isolated DNA encoding the anti-epidermal growth factor receptor single-chain antibody of  claim 12 .  
     
     
         22 . An expression vector comprising the isolated DNA of  claim 21.

Join the waitlist — get patent alerts

Track US2006110324A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.